Guillain-barre Syndrome as one of the Rare Manifestation of Systemic lupus Erythematosus- A Rare Case Report

Authors

Saumya Ranjan Sahoo¹, Taranisen Sethi²

¹Junior Resident, Department of General Merdicine, VIMSAR, Burla
²Junior Resident, Department of General Medicine, VIMSAR, Burla

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disorder being mediated by immunocomplexes and autoantibodies and INF-Alpha is the key mediator. Among neurological manifestations Guillain barre syndrome (GBS) is one of the rare presentation. We described a 35 year female who developed acute onset progressive ascending quadripareisis with tingling and numbness of bilateral lower limb. NCS showed acute motor sensory axonal polyneuropathy. The patient had diffuse non scarring alopecia with anaemia with proteinuria and both ANA and anti –dsDNA were reactive. The patient improved with pulse dose of methylprednisolone and i.v immunoglobin (2gm/kg body weight) and discharged with hydroxychloroquinie and low dose of prednisolone.

Introduction

Systemic lupus erythematosus (SLE) is characterized by heterogeneous, multisystem involvement and the production of an array of autoantibodies, immune complex mediated disease. The complex process is triggered by genes, female hormones, environmental factors like UV light, smoking and infections like EBV. Neuropsychiatric systemic lupus erythematosus (NPSLE) as described by the American College of Rheumatology (ACR) research committee includes 19 neuropsychiatric syndromes divided into neurologic syndromes of the central, peripheral, and autonomic nervous system and the psychiatric syndromes observed in patients with SLE in which other causes have been excluded. These symptoms may precede the onset of SLE or can occur at any time during the course of SLE[¹]. However, to the best of our knowledge, few cases have been reported in the last 50 years in which the initial manifestation of SLE was Gullian–Barre syndrome (GBS)[²]

Case Report

A 35-year-old female presented with tingling and numbness of both the lower limbs with weakness of both the limbs which was sudden onset progressive ascending type and gradually involved both the upper limbs in span of 2 days. She got bed ridden and came under Hugh score 3. There was no bladder and bowel involvement. There was no muscle fasciculation, no headache, nausea, vomiting, no blurred vision, no difficulty in swallowing and drinking. There was no history of vaccination. There was no antecedent fever, loose stool episodes in past 1 month. The patient is not a known case of diabetes mellitus, chronic kidney disease, any thyroid disorder.
On examination patient was afebrile, respiratory rate 18/min, blood pressure of 126/70 mm of Hg. The patient had diffuse non scarring alopecia. On neurological examination tone was diminished in both upper and lower limb with no atrophy. Power was 3/5 proximally and 4/5 distally in both upper and lower limbs. All the DTRs are diminished. Paresthesia was there in distal limbs in gloves and stoking patterns. There was also fine touch and vibration lost up to mid of b/l legs and hands. Lab data showed anemia was there with Hb 10.2 gm/dl. TLC and TPC were in normal limits. Serum urea and creatinine were normal. LFT was normal. There was hypoalbuminemia (albumin was 2.4gm/dl). Urinalysis revealed protein was 3+. 24 hr urine protein came out to be 12.4 gm. The ESR was 45. Serological tests for HIV, hepatitis B/C were negative. The ANA was 8.7 units (>1.2 –Positive), anti-dsDNA was >150 IU/ml(30 IU/ml-positive). Antiphospholipid antibodies were negative. CSF study revealed albumin-cytological dissociation (total protein: 153gm/dl, total cell count: 3/microlit). Contrast MRI was normal. Nerve conduction study revealed non of the Motor Nerve Conduction Velocity (MNCV) and Sensory Nerve Conduction Velocity (SNCV) was generated in any of the four limbs and also F-wave was not generated which was in more favour of motor sensory axonal polynodaradulopathy. The patient was improved with pulse dose of methylprednisolone 1gm daily for 5 days with IVIG 2gm/kg over 5 days. Then the patient was discharged with Hydroxychloroquine, and low dose prednisolone.
Date: 03.10.2021

TEST FOR ANTI-β2GPI (SCREENING)

Results: > 150.00 IU/mL

N.B.
- < 20 IU/mL: Negative
- 20-50 IU/mL: Positive
- > 50 IU/mL: Equivocal

N.B.
LIKE OTHER LAB REPORTS THIS IS FOLC CORRELATED WITH OTHER CLINICAL FINDINGS.

(DR. N. K. Jayodia)

Date: 02.10.2021

TEST FOR ANA (SCREENING)

Results: 8+ Units

N.B.
- < 0.8: Negative
- 0.8-1.2: Equivocal
- > 1.2: Positive
Discussion
The signs and symptoms in the presented patient, fulfilled the Asbury criteria\(^3\) and ACR\(^1\) case definitions for the diagnosis of GBS. Various forms of lupus related polyneuropathy have been reported in 10–20% of patients with SLE\(^4\). However, GBS which is a demyelinating polyneuropathy, is a rare complication in lupus\(^5,6\). The prevalence of SLE with GBS has been reported to be between 0.6% and 1.7%\(^7,8\). The pathogenesis of GBS as a manifestation of active SLE is not clear, but both cell-mediated and humoral processes may play a significant role\(^6\). There are currently four kinds of anti-neuronal antibodies: antilymphocytic antibodies, antiphospholipid antibodies (including cardiolipin antibodies and lupus anticoagulants), and anti-ribosomal P protein antibodies. These antibodies are often present in the plasma and cerebrospinal fluid, and they cause more extensive neurological damage. Corticosteroids, cyclophosphamide, plasmapheresis, and immunoglobulin have been used in AIDP or GBS with SLE according to the previous literature. The combination of corticosteroids and cyclophosphamide is considered the first-line treatment option in a review of the literature\(^9\).

Conclusion
Our case shows GBS can be one of the initial presentations of SLE which was successfully treated by IVIG and pulse dose of
methylprednisolone. Still more researches are required to find the pathogenesis and treatment options of both the disease.

**Conflict of Interests:** No

**References**

1. “The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes,” Arthritis & Rheumatism, vol. 42, no. 4, pp. 599–608, 1999. View at: Publisher Site | Google Scholar

2. Millette TJ, Subramony SH, Wee AS, et al. Systemic lupus erythematosus presenting with recurrent acute demyelinating polyneuropathy. Europ Neurol 1986;25:397–402. [PubMed] [Google Scholar]

3. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain–Barré syndrome. Ann Neuro 1990;27:21-24.

4. Levin KH. Variants and mimics of Guillain–Barre syndrome. Neurologist 2004;10:61–74. [PubMed] [Google Scholar].

5. Chaudhuri KR, Taylor IK, Niven RM, et al. A case of systemic lupus erythematosus presenting as Guillain–Barre syndrome. Br J Rheumatol 1989;28:440–2. [PubMed] [Google Scholar].

6. Robson MG, Walport MJ, Davies KA. Systemic lupus erythema-tosus and acute demyelinating polyneuropathy. Br J Rheumatol 1994;30:314–6. [Google Scholar]

7. Korn-Lubetzki I, Abramsky O. Acute and chronic demyelinating inflammatory polyra-diculoneuropathy. Association with autoimmune diseases and lymphocyte response to human neuritogenic protein. Arch Neurol 1986;43:604–8. [PubMed] [Google Scholar].

8. Nadri Q, Althaf MM. Guillain–Barre syndrome as the initial presentation of systemic lupus erythematosus—case report and review of literature. Ann Saudi Med 2015;35:263–5. [PMC free article] [PubMed] [Google Scholar]

9. van Laarhoven HW, Rooyer FA, van Engelen BG, et al. Guillain-Barre syndrome as presenting feature in a patient with lupus nephritis, with complete resolution after cyclophosphamide treatment. Nephrol Dial Transplant 2001; 16:840–2. [PubMed] [Google Scholar]